**Noninvasively Detection of the Pathological Changes of MS Lesions Responding to Treatment using Diffusion Basis Spectrum Imaging**

**Yong Wang¹, Peng Sun¹, Anne H Cross², and Sheng-Kwei Song¹,³**

¹Radiology, Washington University in St. Louis, Saint Louis, MO, United States, ²Neurology, Washington University in St. Louis, Saint Louis, MO, United States, ³Hope Center for Neurological Disorders, Washington University in St. Louis, Saint Louis, MO, United States

**Introduction** Studying the pathophysiology of diseases of the human central nervous system (CNS) presents a special challenge because the acquisition of tissue samples has the potential of causing harm to patients. This difficulty is compounded when studying a chronic disease such as multiple sclerosis (MS), in which lesions change with treatment and with time. This would require multiple biopsies over multiple time-points to gain a full understanding of pathogenesis. A noninvasive magnetic resonance imaging modality capable of detecting and quantifying the severity and evolution of heterogeneous MS lesion is highly desired. Recently, we have developed such an imaging method, diffusion basis spectrum imaging (DBSI), to simultaneously quantify axonal injury, demyelination, and inflammation in the CNS [1]. Intensive phantom and animal studies have shown that DBSI can accurately quantify CNS myelinated and unmyelinated axons, and cells, edema/extracellular space. Although DBSI holds promise of conducting longitudinal studies on chronic CNS diseases, the feasibility and accuracy of achieving this goal have not yet been well studied. In this study, we first conducted two sequential whole brain DBSI scans to three healthy controls on separate days. ROIs encompassing 70 voxels were enrolled and scanned for multiple times after the initial diagnosis and treatment. The data from this longitudinal study was used to demonstrate DBSI’s capability to trace the pathological substrate changes due to time and pharmaceutical treatment.

**Method Subject:** Three normal healthy controls and one MS patient provided informed consent, after approval of the study by the Washington University Human Research Protection Office/Institutional Review Board. MRI: A 3.0 Tesla Trio TIM (Siemens, Erlangen, Germany) scanner was used to acquire diffusion data. The DBSI data were collected with 2x2x2 mm³ resolution in the transverse plane, covering the whole brain. Diffusion-weighting was applied in 99 directions with max b-value = 2000 s/mm² and TR/TE was 10000/120 ms. The total DBSI acquisition time (one average) with single-shot diffusion-weighted EPI sequence was 15 minutes. High-resolution 1x1x1 mm³ fluid attenuated inversion recovery (FLAIR) images were used for MS lesion identification. T1-weighted 3D magnetization prepared rapid acquisition of gradient echo (MPRAGE) sequences were acquired at 1x1x1 mm³ resolution. **Diffusion Data Preprocessing:** Phase maps were calculated from diffusion data acquired during EPI current acquisition to correct for motion artifacts in EPI images. The diffusion-weighted images were then co-registered to the anatomical MPRAGE, and FLAIR images using FLIRT (FMRIB’s Linear Registration Tool) [2]. **DBSI Analysis:** Eq. [1] was solved by fitting the 99 diffusion weighted signals using a linear combination of diffusion basis sets consisting of cylindrically symmetric diffusion tensors with the freedom to vary $\lambda_i$ and $\lambda_i$, to estimate the number of anisotropic diffusion tensor components ($N_{aniso}$) and the associated principal directions. After $N_{aniso}$ was computed, the number of isotropic component ($N_{iso}$) was further determined using non-negative least-squares (NNLS) analysis [3]. The global nonlinear optimization was conducted employing direct pattern search to solve Eq. [1]. $S_k$ is the kth measured diffusion weighted signals ($k = 1, 2, 3, ..., 99$). $S_i$ and $S_j$ are fractions of anisotropic diffusion components and isotropic diffusion component respectively.

**DBSI Reproducibility Test:** Three healthy controls underwent two DBSI brain scans each on separate days. ROIs encompassing 70 voxels were drawn in the same region of the centrum semiovale for the 3 healthy controls. Axial diffusivity, radial diffusivity, cell ratio, and edema ratio were obtained by fitting the model, and then were compared voxel-wise within the same healthy control for the 2 time-points using Bland-Altman plots.

**Longitudinal Scan of MS Brain Lesions:** One MS patient with five gadolinium enhancing lesions was scanned by DBSI over 4 time-points The first two scans were performed on day 0 and 12, prior to any therapy during the diagnostic evaluation. Scan 3 at day 23 was immediately after 3 doses of 1,000mg IV methylprednisolone, a corticosteroid. Scan 4 was done at day 147, after the patient had received 2 infusions of natalizumab (longer interval from scan 3 to 4). Images from the four scans were co-registered to the anatomical T1W, and T2W images using FLIRT.

**Results and Discussion** Bland-Altman plots for DBSI-derived axial diffusivity, radial diffusivity, cell ratio, and edema ratio (Fig. 1) show that fewer than 5% of voxels differed by more than 2 standard deviations (dotted lines) between repeated scans for the 70 voxels in the centrum semiovale. Our data suggested excellent DBSI reproducibility and indicate feasibility of a planned future longitudinal DBSI study. Over the four DBSI scans of the 5 MS brain lesions, DBSI axial diffusivity was mostly unchanged (Fig.2, A), suggesting the axon injury did not further deteriorate during the study period. DBSI radial diffusivity decreased over the four scans in 4 of 5 lesions (all but lesion 5 in Fig.2, B), suggesting myelin damage was highest at the beginning during enhancement, and subsequently underwent some recovery. In addition, DBSI found that cellularity increased in 3 of 5 lesions (Fig.2, C), which suggests increasing numbers of cells, such as oligodendrocytes. Edema ratio was highest at time 0 and decreased over the four scans in four lesions (all but lesion 4 in Fig.2, D), which may reflect dynamics of blood-brain barrier breakdown and vasogenic edema development and recovery. This study provides a basis for future longitudinal DBSI studies on MS patients. Our goal is to develop improved imaging methods to evaluate the effectiveness of various MS treatments, and ultimately to help to customize patient-specific treatment plans.